Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Doyle

Podiatrist Mountain View, CA Doctor of Podiatric Medicine

NPI 1346603826 CMS profile 6421140

701 E El Camino Real, Mountain View, CA 94040

Open in the dashboard

General payments

$91,683

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Doyle of Mountain View, CA is reported in the CMS Open Payments database as having received $91,683 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53,722 67
2024 General $10,534 21
2023 General $4,677 14
2022 General $6,173 14
2021 General $10,993 36
2020 General $2,547 11
2019 General $3,037 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Doyle
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Matthew Doyle were reported at $53,722. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Matthew Doyle Podiatrist median Middle half National median
2019 $3,037 $196 $72–$601 $163
2020 $2,547 $118 $38–$335 $114
2021 $10,993 $169 $57–$573 $132
2022 $6,173 $220 $74–$782 $149
2023 $4,677 $208 $71–$635 $160
2024 $10,534 $237 $87–$681 $164
2025 $53,722 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $66,937 74 payments
  2. Evolution Surgical, Inc $12,896 37 payments
  3. Synthes GmbH $8,346 18 payments
  4. Stryker Corporation $2,093 17 payments
  5. Kerecis Limited $404 8 payments
  6. Orthofix Medical, Inc. $141 2 payments
  7. DePuy Synthes Sales Inc. $136 2 payments
  8. Smith+Nephew, Inc. $114 2 payments
  9. Paragon 28, Inc. $111 4 payments
  10. Zimmer Biomet Holdings, Inc. $107 1 payment
  11. Other $398 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $57,475 8 payments
  2. Education $12,952 11 payments
  3. Travel and Lodging $10,816 37 payments
  4. Food and Beverage $6,440 113 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $3,000 3 payments
  6. Consulting Fee $1,000 1 payment
Products named General payments · program years 2019–2025
  1. AUGMENT INJECTABLE $617 3 payments
  2. PRIME SERIES $308 1 payment
  3. FUSEFORCE $257 2 payments
  4. INFINITY $253 3 payments
  5. Kerecis Omega3 SurgiClose $243 2 payments
  6. STAR $173 1 payment
  7. VARIAX $168 1 payment
  8. Kerecis SurgiClose Wound Care $162 6 payments
  9. Kerecis GraftGuide $162 6 payments
  10. Kerecis SurgiClose Wound Care $162 6 payments
  11. Other $3,236 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Podiatry: 160

Drug cost

$26

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibuprofen Generic 11 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$81,751

Of which drugs: $89

Medicare patients

423

Average age 75

Services billed

977

259 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 42%
Diabetes 23%
Ischemic heart disease 20%
Chronic kidney disease 19%
Osteoporosis 19%
Atrial fibrillation 16%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 110 $72

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record